Five-country survey found that self-reported dry eye symptoms were more common than reported health care professional diagnosis
Among respondents with self-reported dry eye, many managed their symptoms themselves,
Revenue of $1.375 Billion
Revenue Grew 7% as Reported and 8% on a Constant Currency1 Basis Compared to the Third Quarter of 2025
GAAP Net Income Attributable to Bausch + Lomb Corporation of $32
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas
BL1243 (tonabersat) is being developed as a potential oral treatment for patients with earlier-stage dry AMD, where treatment options remain limited
Clinical development program expected to begin in 2027
Bausch
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 28, 2026. The
Next-generation platform provides precision and control in laser-assisted preparation for premium cataract, LASIK flap and corneal therapeutic surgeries with live swept source OCT
Compact design accommodates
Multicenter retrospective case series published in Ophthalmology and Therapy
Results demonstrate enVista Aspire and enVista Aspire toric deliver good distance and functional intermediate vision in a majority of
Only 14% of peri-, menopausal and post-menopausal women recognize dry eye as a menopause-related symptom.
78% of women were surprised to learn that dry eye is a symptom of perimenopause or menopause.
Women
Dual-action eye drop targeting both evaporative and inflammatory dry eye disease moving to Phase 3
Positive Phase 1b results for ocular surface pain candidate validate TRPV1 antagonist approach and strengthen
LAVAL, QC, Aug. 6, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the board of
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors.
At the request of Bausch Health
Revenue of $1.394 Billion
Revenue Grew 9% as Reported and 8% on a Constant Currency1 Basis Compared to the Second Quarter of 2025
GAAP Net Loss Attributable to Bausch + Lomb Corporation of $14
EyeGility is designed for the enVista® family of IOLs
Offers balanced push force for smooth delivery, convenient one-handed operation
Available now for enVista Aspire™; will be available for enVista Envy™ in the
Phase 2 study did not meet its primary endpoint.
Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of
Designed to reduce the operational burden that stands between physicians and their patients.
Initial offering focuses on pre-surgery cataract education, with additional AI capabilities for ophthalmology planned
